CluenexTeleflex TFX
Teleflex scores weak on business quality (4.0 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Teleflex does
Teleflex manufactures specialized medical devices for vascular access, interventional cardiology, and surgical applications, selling primarily to hospitals and healthcare providers. The company is working to expand its product portfolio and improve operational efficiency across its core segments.
- What it does best
Teleflex excels in free cash flow generation relative to its sector, ranking in the top quartile with a margin of 47%. This cash efficiency provides steady liquidity despite broader operational challenges.
- The main risk
An interest coverage ratio of 2.1x leaves the company highly vulnerable to earnings contractions, as debt servicing consumes a substantial share of operating income.
Quality, check by check
Scored against its own industry, from company filings.
Operating margins stand at 9.0% with a net margin of -39.7% due to a net loss of $1.0B. Profitability remains constrained by high costs relative to gross margins of 53.8%.
The company holds a bottom quartile gross margin rank of 31% within its sector, indicating limited pricing power and vulnerability to competitive pressures from peers like PEN.
Revenue growth registers at 17.2%, outpacing the broader sector's top decile rank of 84. This top-line expansion shows strong momentum compared to historical annual summaries.
Total debt sits at $2.6B with a debt-to-equity ratio of 0.8x, while interest coverage of 2.1x points to tight debt servicing. Free cash flow of $340M supports operations, but the balance sheet is weakening.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
No open market buys or unplanned sales by executives or directors.
Our sealed record on TFX
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Teleflex scores weak on the Cluenex quality check (4.0 of 10), measured against its own industry. Profitability is weak, moat fair, growth steady and financial health weak.
In the last 90 days of SEC Form 4 filings: No open market buys or unplanned sales by executives or directors.
Oct 22, 2026, before the open.
See TFX today
- Today's verdict on TFX, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Teleflex (TFX)”, https://cluenex.com/stocks/tfx/, data as of Oct 10, 2026.